Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma
- 15 July 2001
- Vol. 92 (2) , 207-217
- https://doi.org/10.1002/1097-0142(20010715)92:2<207::aid-cncr1311>3.0.co;2-d
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose IntensityBlood, 1999
- Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin’s lymphomaPublished by Elsevier ,1998
- Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.Journal of Clinical Oncology, 1996
- Vincristine, doxorabicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma — a multicenter phase II studyAnnals of Oncology, 1995
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Gastric Cancer: Adjuvant therapy of gastric cancer: Have we made any progress?Annals of Oncology, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usageCancer, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958